A 38-year-old man with bipolar I disorder is maintained on lithium (level 0.85 mEq/L) but experiences a breakthrough manic episode. He weighs 95 kg. Which augmentation or switch strategy has the best evidence for acute mania?
- A Add carbamazepine to ongoing lithium
- B Add valproate or an atypical antipsychotic (e.g., quetiapine or olanzapine) ✓
- C Switch to lamotrigine monotherapy
- D Add benzodiazepine and increase lithium target to 1.4 mEq/L
Correct answer: B. Add valproate or an atypical antipsychotic (e.g., quetiapine or olanzapine)
Explanation
For breakthrough mania on lithium, evidence-based options include adding valproate or an atypical antipsychotic (olanzapine, quetiapine, risperidone, aripiprazole). Carbamazepine combined with lithium is avoided due to pharmacokinetic interactions (carbamazepine induces CYP3A4, reduces lithium-co-administered drug levels, and the combination carries significant neurotoxicity risk). Lamotrigine is indicated for bipolar depression maintenance, not acute mania. Targeting lithium at 1.4 mEq/L risks toxicity without compelling evidence for superior efficacy.
Reference: Kaplan & Sadock's Synopsis of Psychiatry, 11th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.